SOURCE: CLX Investment Company, Inc.

January 31, 2007 09:57 ET

CLX Investment Company Portfolio Investment Zonda, Inc. Prepares for Distribution of Revolutionary QuikAlert™ Food Safety Product

TEMECULA, CA -- (MARKET WIRE) -- January 31, 2007 --CLX Investment Company, Inc. (OTCBB: CLXN), a diversified investment fund, today announced that portfolio investment Zonda, Incorporated is preparing for worldwide distribution of its revolutionary new food safety product -- QuikAlert™, which rapidly detects potentially dangerous microorganisms, including E. coli, directly from a food product.

Since announcing the launch of QuikAlert™ two weeks ago, Zonda has received inquiries from around the world. Zonda is gathering orders and preparing to have product available for shipment by the end of this week.

Product information, such as the product insert, can be found on Zonda's website, at A product demonstration slideshow can also be accessed on the site. Food industry companies, distributors and even individuals interested in purchasing the QuikAlert™ product can e-mail Zonda at

QuikAlert™ was designed as a first line of defense in detecting food borne pathogens directly from a food product before it is packaged or shipped. Typically, perishable food products are packaged and shipped before pathogen test results are available. QuikAlert™ can detect these potentially dangerous microorganisms in minutes versus hours or days.

QuikAlert™ is a screening tool that enables food companies to detect potentially dangerous levels of microorganisms. A provided swab is used to sample a food product. After 20 minutes, a reagent is added to the tip of the swab. After 2 minutes, a positive test will result in a purple color on the tip of the swab, indicating a presence of potentially dangerous microorganisms.

QuikAlert™ requires no expensive equipment or technical training and no laboratory time or equipment is needed. The QuikAlert™ test can be performed in the field during the growing cycle and at the time of harvest.

"In light of the recent E. coli outbreaks and a growing global concern for food safety, Zonda is expecting a large demand for QuikAlert™, both domestically and in markets throughout the world," said Laurie J. Oleksiewicz, president of Zonda, Incorporated. "The initial reaction to the introduction of QuikAlert™ has been extremely positive, and as word of this product spreads through the food industry, we expect that the interest level will steadily increase."

A 2006 outbreak of E. coli (Escherichia coli) bacteria has sickened scores of people at restaurants in several states. The U.S. Centers for Disease Control and Prevention (CDC) confirmed 71 E. coli cases in five states, most in New Jersey, New York and Pennsylvania plus two in Delaware and one in South Carolina. Nearly three-dozen people fell ill with symptoms consistent with E. coli infection. Investigation by the CDC indicated that shredded lettuce was the most likely source of the outbreak in most of the restaurants. Because multiple restaurants were involved during the same time period, contamination of the lettuce likely occurred before reaching the restaurants. E. coli linked to bagged spinach also killed three people and sickened 206 others in 26 states and Canada in fall of 2006.

According to the CDC, the E. coli infection can cause a complication called hemolytic uremic syndrome (HUS), in which the red blood cells are destroyed and the kidneys fail. About 8% of persons whose diarrheal illness is severe enough that they seek medical care develop this complication. In the United States, HUS is the principal cause of acute kidney failure in children, and most cases of HUS are caused by E. coli.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About Zonda, Incorporated

Zonda, Inc. ( specializes in diagnostic tests that serve the medical, food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda's product line includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and Group A Strep, tests that detect bacterial and other potential harmful micro-organisms on surfaces, and confirmation tests for a wide variety of bacteria. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to PCR or DNA testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.

About CLX Investment Company

CLX Investment Company ( holds a 31% equity interest in Zonda, Inc. ( CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    Email Contact